



Ann GIDNER

PARTNER

AXCELPartners Scandinavia

Ann has had a distinguished career in the Life Sciences industry, spanning Corporate Executive and CEO roles on several continents. She started as a Management Trainee and Head of Operations with Cambrex Pharma in Sweden. She then led Cambrex' initiative into CDMO industry, designing, implementing and growing this business segment to be promoted to several Global Director roles for Cambrex Pharma, based in New Jersey.

Ann then was recruited to Head of Global Marketing & Sales for Lanxess in Leverkusen, Germany, leading a worldwide team of 40 people and more than doubling CDMO revenues in 2 years.

In 2011, she took over the responsibility of Semcon Life Sciences in Lund (Sweden), leading its QA/RA for Medtech and Pharma, CRO services performing Clinical Trials, Management consulting and Engineering departments, before becoming CEO of Monocl, a Life Sciences Strategy consultancy.

In 2014, she was appointed Director of Business Development Licensing for Novozymes Biopharma (Denmark), building an international Licensing platform for biological Half-life Extension technologies for enhanced Drug Delivery.

Since 2014, Ann has held CEO and Board Director positions for Scandinavian publicly listed companies: SenzaGen, AcuCort, SelectImmune Pharma, Iconovo, Ziccum and Thor Medical, applying operational and strategic leadership within Clinical Trials, Drug Toxicity testing, Oral Drug Delivery, Immunotherapy, Drug Delivery Devices, Thermostable Biologics as well as cutting-edge Vaccine and mRNA development.

Educated in Sweden and France, Ann holds a MSc/Chemical Engineering from the Lund Institute of Technology, an MBA from Lund University as well as an MSc/Bioprocédé from the Ecole Nationale Supérieure d'Ingénieurs de Génie Chimique de Toulouse.

Ann will immediately join AXCEL Partners in its Paris office and open AXCEL's office in Lund (Sweden) in January 2026.